.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
US Army
Healthtrust
Federal Trade Commission
Novartis
Fuji
Farmers Insurance
AstraZeneca
US Department of Justice

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Quinuclidine derivatives and medicinal compositions containing the same
Abstract: The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds.
Inventor(s): Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee: Almirall Prodesfarma AG (Baar, CH)
Application Number:11/116,777
Patent Claims: 1. A compound which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

2. The compound according to claim 1 which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1- azoniabicyclo[2.2.2] octane bromide.

3. A pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable carrier or diluent.

4. The pharmaceutical composition of claim 3 comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3 -phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide.

5. The pharmaceutical composition according to claim 3 further comprising a .beta..sub.2 agonist.

6. The pharmaceutical composition according to claim 4 further comprising a .beta..sub.2 agonist.

7. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of a compound according to claim 1.

8. The method according to claim 7 comprising administering to the patient an effective amount of 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane bromide.

9. The method according to claim 7 further comprising administering to the patient an effective amount of a .beta..sub.2 agonists.

10. The method according to claim 8 further comprising administering to the patient an effective amount of a .beta..sub.2 agonist.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Chinese Patent Office
US Army
QuintilesIMS
Johnson and Johnson
McKinsey
Accenture
Boehringer Ingelheim
Novartis
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot